PGE2 Cancer Research Results

PGE2, Prostaglandin E2: Click to Expand ⟱
Source:
Type:
Prostaglandin E2 (PGE2) is a lipid compound that plays a significant role in various physiological processes, including inflammation, immune response, and regulation of cell growth. PGE2 is often found at elevated levels in various types of cancer, including colorectal, breast, and lung cancers. It can promote tumor growth by enhancing cell proliferation, inhibiting apoptosis (programmed cell death), and promoting angiogenesis (the formation of new blood vessels).
- PGE2 is a pain-inducing factor. It is able to sensitize primary sensory neurons and leads to central sensitization and also facilitate the release of pain-related neuropeptides
-Upregulated in AD brain; promotes inflammatory cytokine release, increase ROS, may increase Aβ deposition


Stroke, Cerebral Ischemic Stroke: Click to Expand ⟱
Ischemic stroke is also called brain ischemia and cerebral ischemia. Ischemia is the medical term for "lack of blood supply."

Quick Reference

Mechanism Top Compounds
Blood flow / anti-thrombotic support Aspirin, Ginkgo biloba, Panax notoginseng, Salvia miltiorrhiza
Membrane repair / cholinergic support Citicoline, Alpha-GPC
Antioxidant / ROS control EGCG, Curcumin, Quercetin, Tocotrienols
Anti-inflammatory / NF-κB / cytokines Curcumin, Luteolin, Baicalin
Mitochondrial protection Resveratrol, Citicoline
BBB protection Rosmarinic acid, Astragaloside IV

Stroke/Product Table - Dose + Practical Therapeutic Index

Compound Class Primary Mechanisms Key Stroke Effects Evidence Level Phase Utility Human Dose Range Approx. HED mg/kg/day Practical Therapeutic Index
Aspirin NSAID / anti-platelet COX-1 inhibition; ↓ thromboxane A2; ↓ platelet aggregation Reduces recurrent ischemic stroke risk Strong clinical; standard of care Acute + prevention 81–325 mg/day ~1.2–4.6 mg/kg/day for 70 kg adult High, but bleeding-risk limited
Citicoline / CDP-choline Choline donor Membrane repair; ↑ phosphatidylcholine; ↓ free fatty acid release May support neurological and cognitive recovery Clinical; mixed acute results, better recovery/cognition signal Recovery 500–2000 mg/day ~7–29 mg/kg/day for 70 kg adult Moderate–High
Alpha-GPC Choline donor ↑ acetylcholine; phospholipid support May support post-stroke cognition Clinical; moderate support Recovery 300–1200 mg/day ~4–17 mg/kg/day for 70 kg adult Moderate; TMAO concern
Ginkgo biloba Herbal extract Cerebral blood flow; antioxidant; anti-platelet May support perfusion and cognition Clinical + preclinical Recovery 120–240 mg/day standardized extract ~1.7–3.4 mg/kg/day Moderate; bleeding interaction caution
Panax notoginseng / PNS Saponins Anti-thrombotic; perfusion; anti-inflammatory Improved blood flow/recovery measures in some studies Clinical mainly China + preclinical Acute + recovery Variable extract-dependent Study-specific; often preclinical HED needed Moderate; bleeding interaction caution
Salvia miltiorrhiza / Danshen Herbal extract Microcirculation; vascular protection; anti-platelet May support vascular recovery Clinical mainly China + preclinical Acute + recovery Variable extract/root equivalent Study-specific Moderate; bleeding interaction caution
Baicalin Flavonoid Anti-inflammatory; anti-apoptotic; antioxidant Neuroprotection in ischemic injury models Preclinical + limited clinical Acute No established stroke dose Preclinical HED only Moderate–Low
Curcumin Polyphenol ↓ NF-κB; ↓ cytokines; antioxidant Reduced infarct size/inflammation in models Strong preclinical Acute + recovery 500–2000 mg/day bioavailable form ~7–29 mg/kg/day Moderate; bioavailability limited
Resveratrol Polyphenol SIRT1; mitochondrial protection; anti-apoptotic Reduced apoptosis/infarct injury in models Strong preclinical Acute + recovery 100–500 mg/day ~1.4–7.1 mg/kg/day Moderate; bioavailability limited
EGCG Catechin ROS scavenging; vascular protection Reduced neuronal injury in models Strong preclinical Acute 200–400 mg/day EGCG ~2.9–5.7 mg/kg/day Moderate; liver-dose caution
Quercetin Flavonoid Antioxidant; anti-inflammatory; anti-edema Reduced edema/infarct size in models Strong preclinical Acute 500–1000 mg/day ~7–14 mg/kg/day Moderate
Melatonin Indoleamine Mitochondrial antioxidant; anti-inflammatory Reduced ischemia-reperfusion injury in models Preclinical + limited clinical interest Acute + recovery 3–10 mg/day ~0.04–0.14 mg/kg/day Moderate–High
Tocotrienols Vitamin E subtype Lipid antioxidant; membrane protection Neuroprotection in ischemic models Preclinical + limited clinical Acute 100–300 mg/day ~1.4–4.3 mg/kg/day Moderate
Luteolin Flavonoid NF-κB / Nrf2 / PI3K-Akt modulation Reduced inflammation/neuroprotection in models Strong preclinical Acute No established stroke dose Preclinical HED only Low–Moderate
Ferulic acid Phenolic acid Antioxidant; vasodilation; vascular protection Improved blood flow/reduced injury in models Preclinical Acute No established stroke dose Preclinical HED only Low–Moderate
Rosmarinic acid Phenolic acid BBB protection; antioxidant; anti-inflammatory Reduced BBB disruption in models Preclinical Acute No established stroke dose Preclinical HED only Low–Moderate
Berberine Alkaloid AMPK activation; metabolic/vascular protection Neuroprotection in ischemia models Preclinical Prevention + recovery 500–1500 mg/day ~7–21 mg/kg/day Moderate; interaction caution
Huperzine A Alkaloid AChE inhibition; cholinergic support May support cognitive recovery Preclinical + cognitive clinical context Recovery 100–200 µg/day ~0.001–0.003 mg/kg/day Low–Moderate; narrow cholinergic tolerance
Honokiol Lignan Mitochondrial protection; anti-inflammatory Reduced ischemic neuronal injury in models Preclinical Acute + recovery No established stroke dose Preclinical HED only Low
HED: Human Equilvalent Dose


Scientific Papers found: Click to Expand⟱
2660- AL,    Allicin: A review of its important pharmacological activities
- Review, AD, NA - Review, Var, NA - Review, Park, NA - Review, Stroke, NA
*Inflam↓, AntiCan↑, *antiOx↑, *cardioP↑, *hepatoP↑, *BBB↑, *Half-Life↝, *H2S↑, *BP↓, *neuroP↑, *cognitive↑, *neuroP↑, *ROS↓, *GutMicro↑, *LDH↓, *ROS↓, *lipid-P↓, *antiOx↑, *other↑, *PI3K↓, *Akt↓, *NF-kB↓, *NO↓, *iNOS↓, *PGE2↓, *COX2↓, *IL6↓, *TNF-α↓, *MPO↓, *eff↑, *NRF2↑, *Keap1↓, *TBARS↓, *creat↓, *LDH↓, *AST↓, *ALAT↓, *MDA↓, *SOD↑, *GSH↑, *GSTs↑, *memory↑, chemoP↑, IL8↓, Cyt‑c↑, Casp3↑, Casp8↑, Casp9↑, Casp12↑, p38↑, Fas↑, P53↑, P21↑, CHK1↓, CycB/CCNB1↓, GSH↓, ROS↑, TumCCA↑, Hif1a↓, Bcl-2↓, VEGF↓, TumCMig↓, STAT3↓, VEGFR2↓, p‑FAK↓,
2605- Ba,  BA,    Potential therapeutic effects of baicalin and baicalein
- Review, Var, NA - Review, Stroke, NA - Review, IBD, NA - Review, Arthritis, NA - Review, AD, NA - Review, Park, NA
cardioP↑, Inflam↓, cognitive↑, *hepatoP↑, *ROS?, *SOD↑, *GSH↑, *MMP↑, *GutMicro↑, ChemoSen↑, *TNF-α↓, *IL10↑, *IL6↓, *eff↑, *ROS↓, *COX2↓, *NF-kB↓, *STAT3↓, *PGE2↓, *MPO↓, *IL1β↓, *MMP2↓, *MMP9↓, *β-Amyloid↓, *neuroP↑, *Dose↝, *BioAv↝, *BioAv↝, *BBB↑, *BDNF↑,
2626- Ba,    Molecular targets and therapeutic potential of baicalein: a review
- Review, Var, NA - Review, AD, NA - Review, Stroke, NA
AntiCan↓, *neuroP↑, *cardioP↑, *hepatoP↑, *RenoP↑, TumCCA↑, CDK4↓, cycD1/CCND1↓, cycE/CCNE↑, BAX↑, Bcl-2↓, VEGF↓, Hif1a↓, cMyc↓, NF-kB↓, ROS↑, BNIP3↑, *neuroP↑, *cognitive↑, *NO↓, *iNOS↓, *COX2↓, *PGE2↓, *NRF2↑, *p‑AMPK↑, *Ferroptosis↓, *lipid-P↓, *ALAT↓, *AST↓, *Fas↓, *BAX↓, *Apoptosis↓,
2760- BetA,    A Review on Preparation of Betulinic Acid and Its Biological Activities
- Review, Var, NA - Review, Stroke, NA
AntiTum↑, Cyt‑c↑, Smad1↑, Sepsis↓, NF-kB↓, ICAM-1↓, MCP1↓, MMP9↓, COX2↓, PGE2↓, ERK↓, p‑Akt↓, *ROS↓, *LDH↓, *hepatoP↑, *SOD↑, *Catalase↑, *GSH↑, *AST↓, *ALAT↓, *RenoP↑, *ROS↓, *α-SMA↓,
3264- Lyco,    Pharmacological potentials of lycopene against aging and aging‐related disorders: A review
- Review, Var, NA - Review, AD, NA - Review, Stroke, NA
*antiOx↑, *ROS↓, *SOD↑, *Catalase↑, *GSH↑, *GSTs↑, *MDA↓, *lipid-P↓, *NRF2↑, *HO-1↑, *iNOS↓, *NO↓, *TAC↑, *NOX4↓, *Inflam↓, *IL1↓, *IL6↓, *IL8↓, *IL1β↓, *TNF-α↓, *TLR2↓, *TLR4↓, *VCAM-1↓, *ICAM-1↓, *STAT3↓, *NF-kB↓, *ERK↓, *BP↓, ROS↓, PGE2↓, cardioP↑, *neuroP↑, *creat↓, *RenoP↑, *CRM↑,
3536- MF,    Targeting Mesenchymal Stromal Cells/Pericytes (MSCs) With Pulsed Electromagnetic Field (PEMF) Has the Potential to Treat Rheumatoid Arthritis
- Review, Arthritis, NA - Review, Stroke, NA
*Inflam↓, *Diff↑, *toxicity∅, *other↑, *SOX9↑, *COL2A1↑, *NO↓, *PGE2↓, *NF-kB↓, *TNF-α↓, *IL1β↓, *IL6↓, *IL10↑, *angioG↑, *MSCs↑, *VEGF↑, *TGF-β↑, *angioG↝, *VEGF↓, Ca+2↝,
3404- TQ,    The Neuroprotective Effects of Thymoquinone: A Review
- Review, Var, NA - Review, AD, NA - Review, Park, NA - Review, Stroke, NA
*Inflam↓, AntiCan↑, *TNF-α↓, *IL6↓, *IL1β↓, *NF-kB↓, *iNOS↓, *NRF2↑, *neuroP↑, *MMP↑, *ROS↓, *MDA↓, *GSH↑, *Catalase↑, *SOD↑, *IL12↓, *MCP1↓, *IP-10/CXCL-10↓, *PGE2↓,

Showing Research Papers: 1 to 7 of 7

* indicates research on normal cells as opposed to diseased cells
Total Research Paper Matches: 7

Pathway results for Effect on Cancer / Diseased Cells:


Redox & Oxidative Stress

GSH↓, 1,   ROS↓, 1,   ROS↑, 2,  

Core Metabolism/Glycolysis

cMyc↓, 1,  

Cell Death

p‑Akt↓, 1,   BAX↑, 1,   Bcl-2↓, 2,   Casp12↑, 1,   Casp3↑, 1,   Casp8↑, 1,   Casp9↑, 1,   Cyt‑c↑, 2,   Fas↑, 1,   p38↑, 1,  

Autophagy & Lysosomes

BNIP3↑, 1,  

DNA Damage & Repair

CHK1↓, 1,   P53↑, 1,  

Cell Cycle & Senescence

CDK4↓, 1,   CycB/CCNB1↓, 1,   cycD1/CCND1↓, 1,   cycE/CCNE↑, 1,   P21↑, 1,   TumCCA↑, 2,  

Proliferation, Differentiation & Cell State

ERK↓, 1,   STAT3↓, 1,  

Migration

Ca+2↝, 1,   p‑FAK↓, 1,   MMP9↓, 1,   Smad1↑, 1,   TumCMig↓, 1,  

Angiogenesis & Vasculature

Hif1a↓, 2,   VEGF↓, 2,   VEGFR2↓, 1,  

Immune & Inflammatory Signaling

COX2↓, 1,   ICAM-1↓, 1,   IL8↓, 1,   Inflam↓, 1,   MCP1↓, 1,   NF-kB↓, 2,   PGE2↓, 2,  

Drug Metabolism & Resistance

ChemoSen↑, 1,  

Functional Outcomes

AntiCan↓, 1,   AntiCan↑, 2,   AntiTum↑, 1,   cardioP↑, 2,   chemoP↑, 1,   cognitive↑, 1,  

Infection & Microbiome

Sepsis↓, 1,  
Total Targets: 48

Pathway results for Effect on Normal Cells:


Redox & Oxidative Stress

antiOx↑, 3,   Catalase↑, 3,   Ferroptosis↓, 1,   GSH↑, 5,   GSTs↑, 2,   HO-1↑, 1,   Keap1↓, 1,   lipid-P↓, 3,   MDA↓, 3,   MPO↓, 2,   NOX4↓, 1,   NRF2↑, 4,   ROS?, 1,   ROS↓, 7,   SOD↑, 5,   TAC↑, 1,   TBARS↓, 1,  

Mitochondria & Bioenergetics

MMP↑, 2,  

Core Metabolism/Glycolysis

ALAT↓, 3,   p‑AMPK↑, 1,   CRM↑, 1,   H2S↑, 1,   LDH↓, 3,  

Cell Death

Akt↓, 1,   Apoptosis↓, 1,   BAX↓, 1,   Fas↓, 1,   Ferroptosis↓, 1,   iNOS↓, 4,  

Kinase & Signal Transduction

SOX9↑, 1,  

Transcription & Epigenetics

other↑, 2,  

Proliferation, Differentiation & Cell State

Diff↑, 1,   ERK↓, 1,   MSCs↑, 1,   PI3K↓, 1,   STAT3↓, 2,  

Migration

COL2A1↑, 1,   MMP2↓, 1,   MMP9↓, 1,   TGF-β↑, 1,   VCAM-1↓, 1,   α-SMA↓, 1,  

Angiogenesis & Vasculature

angioG↑, 1,   angioG↝, 1,   NO↓, 4,   VEGF↓, 1,   VEGF↑, 1,  

Barriers & Transport

BBB↑, 2,  

Immune & Inflammatory Signaling

COX2↓, 3,   ICAM-1↓, 1,   IL1↓, 1,   IL10↑, 2,   IL12↓, 1,   IL1β↓, 4,   IL6↓, 5,   IL8↓, 1,   Inflam↓, 4,   IP-10/CXCL-10↓, 1,   MCP1↓, 1,   NF-kB↓, 5,   PGE2↓, 5,   TLR2↓, 1,   TLR4↓, 1,   TNF-α↓, 5,  

Synaptic & Neurotransmission

BDNF↑, 1,  

Protein Aggregation

β-Amyloid↓, 1,  

Drug Metabolism & Resistance

BioAv↝, 2,   Dose↝, 1,   eff↑, 2,   Half-Life↝, 1,  

Clinical Biomarkers

ALAT↓, 3,   AST↓, 3,   BP↓, 2,   creat↓, 2,   GutMicro↑, 2,   IL6↓, 5,   LDH↓, 3,  

Functional Outcomes

cardioP↑, 2,   cognitive↑, 2,   hepatoP↑, 4,   memory↑, 1,   neuroP↑, 7,   RenoP↑, 3,   toxicity∅, 1,  
Total Targets: 84

Scientific Paper Hit Count for: PGE2, Prostaglandin E2
2 Baicalein
1 Allicin (mainly Garlic)
1 Baicalin
1 Betulinic acid
1 Lycopene
1 Magnetic Fields
1 Thymoquinone
Query results interpretion may depend on "conditions" listed in the research papers.
Such Conditions may include : 
  -low or high Dose
  -format for product, such as nano of lipid formations
  -different cell line effects
  -synergies with other products 
  -if effect was for normal or cancerous cells
Filter Conditions: Pro/AntiFlg:%  IllCat:%  CanType:36  Cells:%  prod#:%  Target#:248  State#:%  Dir#:1
wNotes=0 sortOrder:rid,rpid

 

Home Page